ARS Pharmaceuticals, Inc. SPRY
Set alert
At close · Oct 30
After hours · Oct 30, 4:27 PM ET
- YTD
- -70.99%
- 1 year
- -60.79%
- Open
- 3.62
- Prev close
- 3.66
- Mkt cap
- 336.13M
- Vol
- 1.76M
- Avg vol
- 1.66M
- EPS
- -2.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.35
- High
- 3.79
- Forward P/E
- -11.01
- Beta
- 0.83
- Short ratio
- 13.70
- Inst. own
- 95.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2026
- 50-d avg
- 8.64
- 200-d avg
- 9.38
- 1y target
- 28.80
5D chart
Signals (68)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:35 PM | 5 days ago |
| RSI: Oversold | Oct 27, 12:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:00 PM | 5 days ago |
| RSI: Oversold | Oct 27, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| RSI: Oversold | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
News
3 days ago zacks.com
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago globenewswire.com
ARS Pharma to Report Third Quarter 2026 Financial Results
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
3 weeks ago gurufocus.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
[url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Ph
3 weeks ago businesswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
3 weeks ago businesswire.com
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
NEW YORK--(BUSINESS WIRE)---- $SPRY #ARS--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or…
3 weeks ago gurufocus.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 5, 2026LOS ANGELES, Oct. 5,
3 weeks ago gurufocus.com
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYPR NewswireNEW YORK, Oct. 5, 2026NEW YORK,
3 weeks ago prnewswire.com
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b)…
3 weeks ago prnewswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals,…
4 weeks ago newsfilecorp.com
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between…
4 weeks ago newsfilecorp.com
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you…
4 weeks ago newsfilecorp.com
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you…
4 weeks ago newsfilecorp.com
ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between…
1 month ago prnewswire.com
ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June…
1 month ago globenewswire.com
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026…
1 month ago globenewswire.com
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
If you purchased or acquired ARS securities between March 9, 2026, and June 24, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa…
1 month ago newsfilecorp.com
Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026
New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company")…
1 month ago globenewswire.com
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS…
1 month ago globenewswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are…
2 months ago benzinga.com
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.
2 months ago benzinga.com
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
2 months ago benzinga.com
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
ARS Pharmaceuticals (NASDAQ:SPRY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
-
2 months ago benzinga.com
ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 36.96 percent decrease over losses…
3 months ago benzinga.com
Can ARS Pharma's New CEO Unlock Neffy's Potential?
ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
-
3 months ago benzinga.com
ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to…
4 months ago benzinga.com
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
4 months ago benzinga.com
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
4 months ago benzinga.com
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, while consumer discretionary fell 1.1%. Core PCE rose 3.4% in May.
-
4 months ago benzinga.com
Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24
Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.
4 months ago benzinga.com
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
4 months ago benzinga.com
Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3 results and issuing strong guidance. Autozi Internet Technology, Focus Universal, SAGTEC GLOBAL,…
4 months ago benzinga.com
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage
SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.
-
4 months ago benzinga.com
9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
-
4 months ago benzinga.com
ARS Pharma Lowers 2026 Cash Operating Expense Guidance To $248M And Reaffirms Path To Cash-Flow Breakeven In 2027
No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future…
-
4 months ago benzinga.com
ARS Pharmaceuticals Continues To Reduce Cash-Based Operating Expenses After No New Commercial Formulary Additions Or Coverage Decisions Have Been Issued For Neffy In The Latest Cycle
Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy…
-
5 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.
-
5 months ago benzinga.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses…
5 months ago benzinga.com
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.
5 months ago benzinga.com
Dow Settles Above 50,000: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
The CNN Business Fear & Greed Index, a measure of market sentiment, improved slightly on Thursday but remains in the Greed zone at 66.1.
-
5 months ago benzinga.com
ARS Pharmaceuticals Appoints Donn Casale President, Effective June 1
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to…
7 months ago benzinga.com
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.
-
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session